Last week, the Wall Street Journal highlighted the growing role of “virtual biotechs” in scientific breakthroughs and drug discovery. By eliminating the overhead typically associated with brick-and-mortar firms, virtual biotechs can drive drug discovery forward with lean budgets and novel science.
The vast majority of the 62 biotechnology companies currently receiving funding from the Alzheimer’s Drug Discovery Foundation (ADDF) operate virtually. We have long-believed that investing in these businesses is an efficient way to fund high-risk and high-reward Alzheimer’s science.
We’re not alone. According to the Wall Street Journal, “a third of the $4 billion to $5 billion in annual U.S. venture funding for biotech goes to virtual firms.”
Most recently, the ADDF provided Rodin Therapeutics (highlighted in the piece) with more than $180,000 in research funding. Rodin is investigating the value of drugs that affect gene expression on the treatment of neurodegenerative disorders such as Alzheimer’s.
Learn more about the ADDF's diverse portfolio of Alzheimer's drug discovery research.